It’s an exciting time to be studying cures for cancer. New technology like cutting-edge immunotherapy treatments are opening doors to fight the disease, and the outlook for patients today is… Read More
When scientists at Seattle Children’s Research Institute began studying a new immunotherapy cancer treatment a few years ago, they found stunning results. More than 90 percent of children with leukemia… Read More
Seattle Children’s, a hospital and research institute focused on curing childhood diseases, is kickstarting the biggest campaign in its 110-year history. The campaign is called It Starts With Yes and aims… Read More
People with HIV or AIDS are at a much higher risk of developing and dying from cancer — in fact, cancer is now the leading cause of death for people with… Read More
For decades, bone marrow transplants have been a crucial treatment for blood cancers like leukemia and lymphoma — but scientists are still figuring out exactly how the transplants work. Scientists… Read More
CAR T immunotherapies — which genetically program immune cells to fight cancer — hold incredible promise for cancer patients who have run out of other options. But the treatments also… Read More
When you walk into Juno Therapeutics‘ new headquarters in Seattle, your eyes are immediately drawn to the view. The office’s 12th-floor reception desk offers a stunning panorama of the Olympic mountains,… Read More
A new immunotherapy technology developed at Seattle’s Fred Hutchinson Cancer Research Center has been licensed to New York-based Mustang Bio, a subsidiary of Fortress Biotech. The technology is the basis… Read More
CAR T immunotherapies are all the rage in the medical community, reprogramming a patient’s immune system to fight cancer. For some patients, they’ve produced near-miraculous recoveries, and they could be… Read More
Seattle’s Juno Therapeutics, a biotech company developing cutting edge CAR T immunotherapies for cancer, faces a narrow field of competitors. Few other companies in the U.S. are working on CAR T… Read More
Seattle-based biotech company Juno Therapeutics beat analyst expectations in its second quarter revenue Thursday, reporting $21.3 million in revenue for the quarter compared to an analyst estimate of $15.82 million.… Read More
Seattle Genetics, a Bothell, Wash., based biotechnology company developing novel treatments for cancer, announced Monday that it has discontinued the late-stage trial of its treatment for blood cancers after finding… Read More
Seattle-based biotech juggernaut Juno Therapeutics delivered mixed results in its 2017 quarter one earnings report Thursday — the first financial report from the company since it announced it was pulling the… Read More
Seattle-based biotech company Seattle Genetics announced a revenue of $109 million for the first quarter of 2017 Thursday, narrowly beating analyst expectations of $103 million. The company’s stock climbed slightly… Read More
Immunotherapy — treatments that harness the body’s immune system to fight cancer — have seen promising results in blood cancers like leukemia and lymphoma. But those same treatments have proven difficult… Read More
This time last year, Seattle biotech company Juno Therapeutics was on its way to having the first CAR T immunotherapy treatment on the market. But a clinical trial of its… Read More
Juno Therapeutics announced Monday that a former Genentech executive, Dr. Sunil Agarwal, has joined the company as its new President of Research and Development — part of a new office for… Read More
Dr. Matthias Stephan has a vision: cancer-killing immunotherapy that is so cheap and easy to access it replaces chemotherapy as the front-line treatment for cancer. “What I envision is like the… Read More
We often hear that medical research is approaching “breakthroughs” or is at a “tipping point” in innovation. But what does all that really mean? Dr. Nancy Davidson, a longtime breast… Read More
When we think of the immune system, we generally think of one, unified system that works to fight infections and other diseases. But there are actually two distinct parts to… Read More
The Fred Hutchinson Cancer Research Center announced today that it has received a $35 million gift from the Bezos family, the largest single donation in the center’s 41 years of operation.… Read More
Seattle-based cancer immunotherapy company Juno Therapeutics handily beat analyst expectations for the fourth quarter, posting $21.2 million in revenue, compared to an expected $14.6 million, with a loss of 51 cents a… Read More
If the immune system is an army, then T-cells are soldiers on the front lines, attacking invading viruses and other agents of disease. But not every soldier is the same; some… Read More
Silverback Therapeutics, a stealthy biotech startup co-founded by investor, entrepreneur and University of Washington neurosurgery professor Peter Thompson, has raised $10 million in venture funding, according to a filing with the… Read More
Immunotherapy — using the body’s immune system to fight disease — has already made great strides in cancer treatment, with the Seattle region emerging as an epicenter for the approach. But could… Read More
Stephanie Florence is the image of optimism. She is a blonde, bubbly, professional photographer from Lewiston, Idaho, who has a knack for finding something positive just about anywhere. “I love to… Read More
New data from Seattle’s Juno Therapeutics shows promising results for one of its immunotherapy treatments, JCAR017. The drug was studied as a treatment for severely sick patients with non-Hodgkin lymphoma, and the most… Read More
For decades, bone marrow transplants have been an integral treatment for patients with Leukemia and other blood diseases. And now, researchers at Fred Hutchinson Cancer Research Center may be able… Read More
Juno Therapeutics announced last week that it was placing a voluntary hold on its clinical trial of JCAR015 — an experimental but promising immunotherapy treatment for patients with advanced leukemia —… Read More
Juno Therapeutics, the Seattle-based biotech company developing immunotherapy treatments for cancer, announced it has placed a voluntary hold on the clinical trial of its JCAR015 cancer treatment, following two patient deaths… Read More